FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

CMC Comparability Protocol Guidance

FDA publishes a final guidance on using comparability protocols for postapproval changes in chemistry, manufacturing, and controls information in NDAs...

latest-news-card-1
Human Drugs

Distributed Manufacturing Discussion Paper

FDA solicits input on a discussion paper raising regulatory issues and questions about direct manufacturing and point-of-care manufacturing of drugs.

latest-news-card-1
Marketing

OPDP Wants to Research Drug Name Interpretation

The CDER Office of Prescription Drug Promotion says it wants to research how consumers and healthcare providers interpret prescription drug names.

latest-news-card-1
Human Drugs

Regener-Eyes Illegally Selling Dry Eye Product

FDA says Palm Harbor, FL-based Regener-Eyes is illegally marketing its Regener-Eyes Ophthalmic Solution.

latest-news-card-1
Federal Register

FDA Extends Comment Period on LASIK Labeling Guide

Federal Register notice: FDA extends the comment period for a draft guidance entitled Laser-Assisted In Situ Keratomileusis (LASIK) Lasers Patient La...

latest-news-card-1
Federal Register

FDA Unveils Device Development Advisory Pilot

Federal Register notice: FDA announces a voluntary Total Product Life Cycle Advisory Program pilot that was agreed to between FDA and industry as part...

Biologics

FDA Lowers Covid Bivalent Booster Age

FDA expands the emergency use authorization for the Moderna and Pfizer/BioNTech bivalent Covid vaccine booster shots to cover children age six and old...

Human Drugs

Evofem Biosciences Ends STI Drug Development

Evofem Biosciences discontinues its EVO100 development program of a drug to prevent chlamydia and gonorrhea in women.

latest-news-card-1
Human Drugs

17 Observations on Empower Pharmacy FDA-483

FDA releases the form FDA-483 with 17 observations from an inspection at the Houston, TX-based Empower Pharmacy outsourcing facility.

latest-news-card-1
Human Drugs

Rolling NDA Filed for OTC Opioid Overdose

Harm Reduction Therapeutics submits the first module of a planned rolling NDA for RiVive (3 mg intranasal naloxone), indicated as an over-the-counter ...